BRD9 expression was positively related with MSI in bladder urothelial carcinoma (BLCA), LUAD, LUSC, SARC and STAD, and negatively related with that in DLBC and pheochromocytoma and paraganglioma (PCPG) (Figure S1B). Here, BRD9 is linked to bladder transitional cell carcinoma.